Globenewswire | July 25, 2023
Tango Therapeutics, Inc. a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers. TNG260 is a first-in-class inhibitor of the CoREST complex .
“The TNG260 phase 1/2 clinical trial is the first trial to use genetic patient selection in combination with checkpoint inhibitor therapy to reverse the cancer-specific immune evasion caused by STK11 loss of function mutations. Resistance to immunotherapy is a major challenge faced by patients with STK11-mutant cancers, which TNG260 is specifically designed to overcome,” said Adam Crystal, M.D., Ph.D., President of Research and Development of Tango Therapeutics. “Our pipeline of precision oncology treatments based on synthetic lethality has advanced significantly this year, as we now have initiated three clinical trials.”
The phase 1/2 trial will evaluate the safety, pharmacokinetics (PK), pharmacodynamics and efficacy of TNG260, with a one cycle single agent run-in phase to evaluate the safety and PK of TNG260, in combination with pembrolizumab, in patients with locally advanced or metastatic solid tumors with an STK11 loss-of-function mutation. STK11 loss-of-function mutations occur in approximately 15% of non-small cell lung cancer, 15% of cervical, 10% of carcinoma of unknown primary, 5% of breast and 3% of pancreatic cancers. Based on preclinical xenograft studies and retrospective clinical analyses, the majority of STK11-mutant cancers are thought to have primary resistance to checkpoint inhibition.
The CoREST complex plays a central role in regulating immunomodulatory signaling in STK11-mutant cancers. In preclinical studies, TNG260 reverses the immune evasion effect of STK11 loss-of-function mutations, restoring sensitivity to an anti-PD-1 antibody, inducing complete remissions in the majority of animals and creating immune memory that prevents re-implantation and regrowth of the tumor.
In April 2023, the U.S. Food and Drug Administration granted Fast Track designation for TNG260 in combination with an anti-PD-1 antibody for the treatment of patients with previously treated advanced non-small cell lung cancer with STK11-mutations.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
Cell and Gene Therapy, Industry Outlook
Businesswire | July 17, 2023
Slingshot Biosciences, Inc. a leading provider of cell mimic control products, is proud to announce the launch of its new SpectraComp fluorescent protein series collection. This groundbreaking series provides scientists with a cutting-edge fluorescent protein control platform for use in flow cytometry analysis.
By genetically modifying T cells and other immune cells in humanized mice to express fluorescent reporter proteins, including eGFP and mCherry, scientists are able to observe live cell, tissue locations, and track protein trafficking. These mechanisms are important when exploiting and redirecting synthetic chimeric antigen receptors (CARs). These tools also serve as effective reporters for gene deletion/expression in modified mice. Explore the endless possibilities of our on-demand cell mimic control platform and unlock new discoveries today. Slingshot’s new SpectraComp series collection of cutting-edge fluorescent proteins: SpectraComp eGFP and SpectraComp mCherry, exceptional controls for unmixing, compensation, and benchmarking for flow cytometry analysis.
“We are thrilled to bring this revolutionary technology to the scientific community,” says Dr. Jeffrey Kim, CEO of Slingshot Biosciences. “Our SpectraComp eGFP and mCherry will provide researchers with an on-demand cell mimic control platform that will allow them to explore the endless possibilities of flow cytometry analysis and unlock new discoveries today.”
This launch of the SpectraComp eGFP and mCherry reaffirms Slingshot Biosciences' commitment to delivering innovative solutions that empower researchers worldwide. These fluorescent proteins will provide scientists with the tools they need to unlock new insights, accelerate discoveries, and push the boundaries of scientific exploration.
About Slingshot Biosciences
Slingshot Biosciences is a leading biotechnology company dedicated to advancing scientific research through innovative solutions. With a focus on developing cutting-edge tools for fluorescence imaging, the company aims to revolutionize how scientists explore and understand the intricate mechanisms of life. Slingshot Biosciences is committed to empowering researchers with exceptional products that enable groundbreaking discoveries and shape the future of bioscience.
Globenewswire | August 09, 2023
Olink Holding AB announced that the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering.
Understanding the complex biological mechanisms of human diseases is essential to identifying effective new therapeutic strategies. The addition of Olink proteomic technology enables a more thorough understanding of the intricate connections between genes, proteins, and diseases that will lead to improved diagnostics, targeted therapies and the advancement of precision and personalized medicine.
“We are immensely pleased to see the Olink Explore HT platform implemented at one of the world’s leading multiomic research centers,“ said Jon Heimer, CEO, Olink Proteomics. “The massive genomic sequencing and automation capabilities of the BCM-HGSC unlocks a unique opportunity for proteogenomic research at scale. We look forward to seeing our tools applied across a broad spectrum of new therapeutic research fields to enhance the existing knowledge of molecular pathways involved in the development, progression, and outcome of disease.”
Other large-scale research programs, like the UK Biobank health study, have demonstrated how Olink Explore enables a more complete understanding of the molecular basis of disease. With the addition of Olink proteomics technology, the BCM-HGSC further strengthens its ability to offer unique multiomics capabilities for large population-scale health studies.
“Technology development and the adoption of new methods remains a priority at the HGSC, and we are excited to incorporate Olink’s technology into our portfolio,” said Richard Gibbs, Ph.D. Director, Human Genome Sequencing Center and Wofford Cain Professor of Molecular & Human Genetics, Baylor College of Medicine. “The ability to perform high-throughput proteomics opens many possibilities for current and future studies. This technology provides a natural extension from traditional genomic research by providing data that points to the impact of genetic variation on function. A comprehensive, multiomic approach will be needed to determine the mechanism of action of many genetic diseases and is essential for guiding effective prevention and treatment.”
The Olink Explore platform represents the cutting edge in proteomic technology. Olink Explore HT is the company's latest solution for high-throughput proteomics, delivering unmatched specificity, scalability, and simplicity. With a completely reimagined and streamlined workflow, Olink Explore HT allows scientists to accurately measure over 5,300 proteins using only 2µl of sample. By combining Olink PEA technology with an NGS readout of relative protein concentrations each thoroughly validated assay maintains the exceptional standards of specificity and sensitivity that Olink users have come to trust.
Olink Holding AB is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.